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Abstract
Background: Dystrophic epidermolysis bullosa (DEB), a rare genodermatosis, is characterized by the formation of
intra-epidermal blistering and the development of chronic nonhealing skin wounds. Recently, attempts have been
made to develop cell-based therapies for this currently intractable disorder. The molecular mechanisms that govern
directional migration of the adult stem cells, allowing their efficient and controlled homing to the skin affected
with DEB, are poorly understood. The key mechanism that regulates recruitment of leukocytes and progenitor stem
cells to distal anatomical tissues affected with disease is chemotaxis, which depends on the signaling molecules,
chemokines, and acts primarily as part of the host defense and repair mechanism.
Methods: Comprehensive proteomic screening of chemokines in the blister fluids of DEB-affected mice was
conducted to define the inflammatory and immune activities, thus providing potential to examine local biological
mechanisms and define the protein signature within lesional skin as a potential marker of disease activity. Also, the
therapeutic relevance of identified chemotactic pathways was investigated in vivo, providing a basis for future
clinical investigations.
Results: Assessment of blister fluid-derived chemokines showed a persistent presence of several chemotactic
molecules, including CXCL1 + 2 and CXCL5. The majority of blister-originated chemotactic signals were associated
with preferential recruitment of CD45+CXCR2+ and CD11b+CXCR2+ leukocytes. Systemic transplantation of an
enriched CXCR2 population of mouse adipose-derived stem cells (mADSC) into DEB-affected mice demonstrated
effective recruitment of cells to the blistering skin under the influence of blister-derived ligands and deposition of
therapeutic type VII collagen.
Conclusions: Collectively, these studies demonstrate that recruitment of mADSC into DEB skin is tightly controlled
by disease-site chemotactic activities and suggest a potential mechanism for effective application of therapeutic
stem cells for DEB.
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Background
Dystrophic epidermolysis bullosa (DEB) is the mechan-
obullous disorder characterized by complete lack or
dysfunction of type VII collagen, resulting in separation
of the dermal–epidermal junction (DEJ) below the lam-
ina densa following minor or insignificant trauma to
the skin [1]. During the past two decades, various
therapeutic approaches have been proposed and tested
in preclinical and clinical settings [2]; however, effective
therapies allowing correction of this debilitating dis-
order remain to be developed.
In recent years, adult stem cell-based therapy was sug-
gested as a potential approach to attenuate DEB progres-
sion. We and others have demonstrated that adult stem
cells (ASC) of different origins (bone marrow, adipose
tissue, blood vessels, and umbilical cord) produce a rep-
ertoire of extracellular matrix proteins, including type
VII collagen, and a plethora of signaling molecules, such
as growth factors and cytokines [3–8]. Also, we showed
that intracutaneous transplantation of genetically normal
ASC from bone marrow into DEB-affected mouse skin
restores the DEJ via direct donation of the therapeutic
type VII collagen [8]. These studies provided proof-of-
concept data suggesting that adult stem cell-derived
connective tissue proteins can participate directly in res-
toration of defective extracellular matrix and demon-
strating the feasibility of systemic cellular therapy for
DEB. In fact, data collected from ongoing clinical studies
aimed at the application of whole bone marrow and
bone marrow-derived mesenchymal stem cells (MSC)
for DEB treatment showed that systemic allotransplanta-
tion accelerates wound healing, enhances angiogenesis,
inhibits inflammation, and alleviates symptoms associ-
ated with the disease [9, 10]. However, despite encour-
aging results, these trials revealed that the majority of
curative effects resulted from the secretion of various
paracrine factors elicited by transplanted cells rather
than from donation of the therapeutic protein to the af-
fected cutaneous tissue [11].
Successful application of ASC for the correction of
genodermatoses, including DEB, and treatment of
chronic wounds which often accompany these disorders,
mainly depends on the efficacy of stem cell homing to
the damaged skin and is considered a major issue in
stem cell-based therapy. The paucity and inefficient mi-
gration of ASC to the damaged skin have been docu-
mented in multiple wound healing studies [12, 13]. The
causatives of the inefficient homing of ASC are still not
defined but current data suggest that these deficiencies
may arise, in part, due to poor extravasation of ASC
from circulation into the cutaneous tissue. The molecu-
lar mechanisms regulating trafficking of the ASC to the
skin, especially blistering skin, are poorly understood.
Under physiological conditions, the key mechanism that
regulates cell migration is chemotaxis, which depends
on signaling molecules, chemokines. Being secreted from
cells in damaged peripheral tissue, chemokines recruit
chemokine receptor-expressing cells, such as leukocytes,
and possibly stem cells as part of host defense and repair
mechanisms. The crucial role of chemokines in direc-
tional migration of ASC to various tissues, such as the
heart, lung, bone marrow, and intestine, has been dem-
onstrated previously [14, 15]. Thus, knowledge of che-
mokines expressed by the targeted tissue and cognate
chemokine receptors expressed on the surface of the
targeted stem cells is a prerequisite for successful tar-
geting of therapeutic ASC. The primary challenge is
therefore to integrate our current knowledge of chemo-
taxis into a rational design of the guidance system to
recruit ASC to the skin affected by certain genoderma-
toses, such as DEB.
Because ASC are naturally involved in the regener-
ation/repair of multiple tissues, expression of chemokine
receptors in ASC from various sources has been studied
widely. Collectively, these data indicate that ASC express
a limited repertoire of functional chemokine receptors
[6, 16, 17]. Moreover, responsiveness of ASC to only a
few chemokines was tested experimentally [16, 18–22].
To the contrary, from our knowledge of chemotaxis in
repair processes, very limited information is currently
available regarding chemotactic signals in the skin af-
fected by various forms of hereditary blistering disorders.
Skin-derived chemokines have been mostly characterized
in association with recruitment of leukocytes during
acute and chronic inflammation [23]. Elevated levels of
CXCL12 and CCL21 were reported in blister fluids fol-
lowing skin burns, lichen planus, and cutaneous lupus
erythematosus, where inflammatory and immune re-
sponses were supported by the recruitment of CXCR4+
and CCR7+ leukocytes, respectively [24–26]. However,
wide expression of CXCL12 in multiple organs does not
provide desirable specificity of ASC migration leading to
significant “dilution” of the therapeutic effect. Import-
antly, the CXCL12–CXCR4 chemotactic axis was also
shown to be responsible for the entrapment of system-
ically administered ASC in lungs. For the same token, it
was suggested that an endogenously high level of
CCL21 in secondary lymphoid organs is responsible for
the observed nonspecific distribution of systemically
transplanted ASC [27]. Collectively, these observations
strongly suggest the need for alternative chemotactic
pathways to target ASC specifically to the skin.
Based on current knowledge of T-cell trafficking [23],
it is plausible that systemically transplanted ASC can be
recruited from circulation to the skin by the activation
of specific receptors on the surface of transplanted stem
cells, followed by transcutaneous migration mediated by
stem cell receptors under the influence of the DEB skin-
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derived chemokines. In this study, we conducted prote-
omic screening of chemotactic molecules in the blister
fluids of DEB-affected mice, the model for severe auto-
somal recessive DEB, to define the inflammatory and im-
mune activities during the active disease state. Pair-wise
comparison of identified chemokines in blister fluids and
receptors on the surface of mouse adipose-derived stem
cells (mADSC) allowed us to define potential chemotac-
tic axes for targeting of the cells into the blistering skin.
We investigated the therapeutic relevance of identified
chemotactic pathways in vivo, providing a basis for fu-
ture clinical investigations. Identified molecules provided
insight into the mechanisms that govern directional mi-
gration and intracutaneous trafficking of systemically in-
fused stem cells, thus permitting broad and effective
application of the therapeutic cells for DEB treatment.
Methods
Mouse strains
Wild-type C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). Transgenic
type VII collagen-deficient (Col7a1–/–) mice were gener-
ated in the Department of Dermatology and Cutaneous
Biology, Thomas Jefferson University [28]. Transgenic type
VII collagen-deficient hypomorphic (Col7a1f lNeo/f lNeo)
mice were obtained from Freiburg Institute for Advanced
Studies, Germany [29]. Both mouse models recapitulate
the clinical, genetic, and ultrastructural features of hu-
man DEB. Targeted inactivation of the Col7a1 gene
generated a severely affected collagen VII knockout
mouse (Col7a1–/–), which is born with extensive cuta-
neous blistering and rapid demise during the first
2 weeks of life due to complications arising from blis-
tering in the skin, oral mucosa, and esophagus and
imbalanced digestion by the gastrointestinal track. The
second model, a collagen VII hypomorphic mouse
(Col7a1f lNeo/f lNeo) which had 10 % of the normal colla-
gen VII levels in the skin, developed all of the symp-
toms of severe RDEB but the presence of one-tenth of
normal full-length type VII collagen confers a milder
phenotype and better prognosis than that in Col7a1
knockout mice.
Blister fluid collection from DEB-affected mice
Col7a1–/– and Col7a1f lNeo/f lNeo mice are born with a
blistering phenotype. Hemorrhagic blisters are readily
developed on paws and other parts on the body (e.g., ab-
domen, armpit, neck). The blister fluids were collected
by needle piercing with an attached syringe, cleared by
centrifugation, and stored at –70 °C until testing.
Chemokine antibody arrays
Proteome Profiler™ Mouse Chemokine Antibody Array
(R&D Systems, Minneapolis, MN, USA) was employed
to assay blister fluid samples derived from Col7a1–/– and
Col7a1f lNeo/f lNeo mice, respectively. Twenty microliters
of blister fluid was used to probe the chemokine anti-
body arrays according to the manufacturer’s instructions.
Chemokine antibody array membranes were developed
by standard enhanced chemiluminescence techniques as
advised by the manufacturer. Acquisition of signals on
mouse chemokine arrays was quantitatively determined
using ScanAlize version 2.50 (Stanford University) and
GEArray Expression Analysis Suite 2.0 software
(SABiosciences, Frederick, MD, USA), which reads the
images and matches them to the corresponding pro-
tein on the array. The net level of each protein was
calculated by the mean of the individual spot intensity
minus the mean of the background intensity. To provide
normalization, the average level ratio of two principal
genes was determined and introduced as a correction fac-
tor. Relative spot intensities are presented as mean ± SD.
Microsoft Excel (Microsoft, Redmond, WA, USA) was uti-
lized for statistical analysis.
Isolation of mADSC and tissue culture conditions
mADSC were isolated from subcutaneous fat of wild-type
C57 BL/6 J mice. Following collection, specimens were
washed in PBS + 1 % Pen/Strep (Gibco, Grand Island, NY,
USA) twice, minced into small pieces, and digested in col-
lagenase solution (0.1 μg collagenase I (Sigma, St. Louis,
MO, USA) in 1 ml PBS and bovine serum albumin (BSA)).
To obtain a single cell suspension, the digested tissue was
applied to a 30 μm mesh separation filter (Miltenyi Biotec,
Auburn, CA, USA). PBS + 1 % BSA solution was added to
the mesh to quench the enzyme and flush any remaining
cells through the filter. The suspension was centrifuged
and the pellet was resuspended in 1 ml of DMEM/F12 and
Glutamax + 10 % FBS (Gibco). Cells were plated in
DMEM/F12 and Glutamax + 10 % FBS (Invitrogen, Grand
Island, NY, USA) and grown to confluence. The adherent
cells (passage 0) underwent negative selection using mag-
netic beads (MACS; Miltenyi Biotec) to remove contamin-
ating endothelial CD31+ and mononuclear CD45+ cells.
Briefly, cells were released by trypsin and centrifuged at
300 × g. The pellet was suspended in 2 mM EDTA and
0.5 % BSA (MACS buffer), mixed with CD31+ and CD45+
tagged microbeads, and incubated at 4 °C for 15 minutes.
After centrifugation, the cells were suspended in MACS
buffer and passed through an LS Separation Column
mounted in the QuadroMACS separator magnetic unit.
The resultant CD31–CD45– mouse cell population defined
as mADSC was grown in standard DMEM/F12 and Gluta-
max + 10 % FBS media unless stated otherwise.
Fluorescence-activated cell sorting analysis of mADSC
mADSC were grown until confluent, trypsinized, and
pelleted by centrifugation at 200 × g for 5 minutes. For
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fluorescence-activated cell sorting (FACS) analysis,
~1.0 × 105 cells were resuspended in 100 μl FACS buf-
fer containing 1 % fetal bovine serum in PBS. For FACS
analysis of surface receptors, each sample was incu-
bated for 30 minutes at 4 °C with FITC-conjugated,
Alexa488-conjugated, PerCP/Cy5.5-conjugated, PE-
conjugated, or Alexa Fluor-647-conjugated antibodies
against the surface markers CCR2, CCR3, CCR4, CCR5,
CCR6, CCR7, CCR9, CCR10, CXCR1, CXCR2, CXCR3,
CXCR4, CXCR6, CXCR5, CXCR6, and CXCR7
(eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. After incubation, the la-
beled cells were diluted with 2 ml of FACS buffer, pel-
leted and resuspended in 300 μl of FACS buffer.
Generally, ~5 × 104 cells were analyzed per sample
using the Guava flow cytometer (BD Biosciences, San
Jose, CA, USA). Results were analyzed using GuavaSoft
2.7 software (BD Biosciences).
Generation and characterization of CXCR2-overexpressing
mADSC
Full-length mouse Cxcr2 receptor with 3′ UTR was
amplified from total mouse RNA via reverse transcrip-
tion reaction using the Superscript II RT Kit (Invitrogen,
Carlsbad, CA, USA) followed by PCR using PFU II high
fidelity polymerase (Agilent Technologies, Santa Clara,
CA, USA). Resultant cDNA was inserted into pEF2-
TOPO vector. Integrity of the promoter and cDNA was
verified by direct DNA sequencing. Minimally cul-
tured mADSC (passages 1–2) were nucleofected with
resultant plasmid (pEF1-mCxcr2) using Lonza nucleo-
fection reaction (T-27 program, nucleofection kit V;
Lonza, Cologne, Germany). Further, a pool of CXCR2-
expressing cells was selected with Blasticidin (0.5 mg/ml;
Invitrogen) for 10 days. Expression of CXCR2 in selected
cells was confirmed by FACS and indirect immuno-
fluorescence analyses. Surface expression of CXCR2
was determined by FACS using PE-conjugated antibodies
as already described. For indirect immunofluorescence,
CXCR2 immunocomplexes were detected with Alexa-
Fluor488-conjugated secondary antibodies (Invitrogen).
Nuclei were counterstained with 4′,6-diamidino-2-phenyl
indol (DAPI; Sigma). Immunofluorescent images were ob-
tained on a Nikon TS100F fluorescent microscope (Nikon,
Melville, NY, USA).
Labeling CXCR2+ mADSC and transplantation
into Col7a1–/– mice
All animal procedures were performed in accordance
with the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health publication no.
86-23) and approved by the Institutional Animal Care
and Use Committee of the Thomas Jefferson University.
For all transplantation studies, mADSC (passages 2–4)
isolated from wild-type C57BL/6 J were labeled with a
red lipophilic tracer DiOC18 (Molecular Probes, Grand
Island, NY, USA) as we described previously [6]. For
systemic transplantation, the 1–2-day-old Col7a1–/–
neonates (n = 5/time point) received 0.6 × 106–0.8 × 106
cells in 10–15 μl PBS per mouse intraperitoneally. For
direct viewing, transplanted cells were detected using
an IVIS live-imaging system (IVIS Lumina XR; Caliper
LifeSciences, Alameda, CA, USA). To avoid detection
of autofluorescence, the exposure time of all imaged
animals was minimized to a maximum of 1 second.
Histological and immunofluorescent analyses
Collected skin tissue was embedded into OCT com-
pound (VWR, Radnor, PA, USA), frozen, and cryo-
sectioned at a thickness of 7 μm. For histological
analysis, sections were stained with H&E using a
standard protocol. For direct viewing of transplanted
mADSC, sections were fixed with 10 % formalin,
stained with DAPI (Sigma) and evaluated using fluor-
escence microscopy. For indirect immunofluorescent
analysis, cross-sections were stained with the follow-
ing primary antibodies: goat anti-mouse CD45 poly-
clonal (BD Bioscience), rat anti-mouse CD11b
monoclonal (BD Bioscience), rabbit anti-CXCR2
polyclonal (Bioss, Woburn, MA, USA), mouse anti-
FLuc monoclonal (Abcam, Cambridge, MA, USA),
rabbit anti-type VII collagen polyclonal (Millipore,
Billerica, MA, USA), and goat anti-type IV collagen
polyclonal (Millipore). Immunocomplexes were detected
with AlexaFluor488-labeled and AlexaFluor594-labeled sec-
ondary antibodies (Invitrogen), respectively. Nuclei were
counterstained with DAPI. Immunofluorescent images
were obtained on a Nikon TS100F fluorescent micro-
scope (Nikon). For analysis of the type VII collagen
deposition, stained sections were analyzed using
AutoQuant imaging software (AutoQuant Imaging
Inc., Troy, NY, USA).The average value of the base-
ment membrane zone (BMZ)-accolated fluorescence
was calculated based on the ratio of the average
value of the total fluorescence of wild-type skin (des-
ignated as 100 %) and the relative percentage of
fluorescence in the skin of transplanted mice. Differ-
ences in fluorescence intensities were assessed using
a Student’s t test, with p < 0.01 considered significant
in all tests.
Statistical analysis
All data are expressed as mean ± SD. Statistical sig-
nificance was assessed using two-tailed type 2 Stu-
dent’s t test, where differences with p < 0.05 were
considered significant.
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Results
Proteomic screens of chemotactic molecules in
DEB-affected mouse skin
The chemokine expression profiles in blister fluids of
Col7a1–/– knockout mice and Col7a1f lNeo/f lNeo hypo-
morphic mice were studied using Proteome Profiler™
Mouse Chemokine Antibody Array allowing the detec-
tion and quantification of 35 distinct chemotactic mol-
ecules. The chemokine arrays were probed using
blister samples collected from blistering skin of mice.
Proteomic screens of blister fluids collected from
Col7a1–/– (n = 5) and Col7a1f lNeo/f lNeo (n = 5) mice
showed consistently high levels of several chemotactic
molecules, including CCL6, chemerin, CCL8, CCL9/
CCL10, CCL12, CXCL1, CXCLl2, CXCL5, and CDF
(Fig. 1a).
The analysis of biological function of identified che-
mokines suggested potential inflammatory infiltrate in
blistering skin. For example, CCL6 has only been identi-
fied in rodents and is a potent chemoattractant of mac-
rophages as well as B cells, CD4+ lymphocytes, and
eosinophils. In mice, CCL6 is expressed in cells from
neutrophil and macrophage lineages, and can be induced
under conditions suitable for myeloid cell differentiation.
The cell surface receptor for CCL6 is believed to be the
chemokine receptor CCR1. Chemerin, also known as
retinoic acid receptor responder protein 2 (RARRES2), is
a chemoattractant protein that acts as a ligand for the G
protein-coupled receptor CMKLR1, also known as
ChemR23. Chemerin was found to stimulate chemotaxis
of dendritic cells and macrophages to the site of inflam-
mation. CCL8, also known as monocyte chemoattractant
protein 2 (MCP-2), is chemotactic for and activates
many different immune cells, including mast cells, eosin-
ophils, and basophils as well as monocytes, T cells, and
NK cells that are involved in the inflammatory response.
CCL8 elicits its effects by binding to several different cell
surface receptors, including CCR1, CCR2B, and CCR5.
CCL9/CCL10, also called macrophage inflammatory
protein-1 gamma (MIP-1γ), macrophage inflammatory
protein-related protein-2 (MRP-2), or CCF18, in rodents
attracts dendritic cells that possess the cell surface mol-
ecule CD11b and the chemokine receptor CCR1. CCL9
is constitutively expressed in macrophages and myeloid
cells. CCL12, also known as monocyte chemotactic pro-
tein 5 (MCP-5) or MCP-1-related chemokine, specific-
ally attracts eosinophils, monocytes, and lymphocytes.
Its expression can be hugely induced in macrophages.
CCL12 is a ligand for CCR2. CXCL1/2/3, also known as
growth-regulated oncogene (GRO), can bind with high
affinity to the IL-8 receptor type B and is a very potent
neutrophil attractant and activator. CXCL5, also known
as epithelial-derived neutrophil-activating peptide 78
(ENA-78), is produced following stimulation of cells
with the inflammatory cytokines interleukin-1 or tumor
necrosis factor alpha. CXCL5 is well known to have
chemotactic and activating functions on neutrophils,
mainly during acute inflammatory responses. This che-
mokine stimulates the chemotaxis of neutrophils posses-
sing angiogenic properties and has been implicated in
connective tissue remodeling. The cell surface receptor
for CXCL5 is the chemokine receptor CXCR2.
Collectively, all identified molecules are prominent
chemotactic factors that activate and attract a variety
of inflammatory cells to the sites of inflammation
produced by tissue injury or disease. Also, the identi-
fied chemokine profiles provided several potential
lead-chemotactic gradients, including CCL6–CCR1,
CCL8–CCR1/CCR5, CCL9/10–CCR1, CCL12–CCR2,
CXCL1/2–CXCR2, and CXCL5–CXCR2, for efficient
recruitment of therapeutic stem cells into the skin af-
fected with blisters.
Expression profile of chemokine receptors in mADSC
The presence of active chemokine receptors on
mADSC was examined in order to determine potential
migratory ability upon in-vivo transplantation into
mice. A series of mADSC preparations were generated
from subcutaneous fat of C57BL6J mice (n = 5), repre-
senting actively dividing cultures at early passage (pas-
sage 2). Cell surface expression for receptors on the
primary mADSC was characterized by FACS analysis
using fluorescently-labeled receptor-specific antibodies
against a panel of available mouse chemokine receptors.
The analysis showed that the mADSC express the lim-
ited repertoire of functional receptors, consistent with
the published profiles from mouse adipose tissue
(Fig. 1b). The overall level of receptor expression
showed consistent reproducibility in all tested mADSC
cultures.
The expression of chemokine receptors appeared het-
erogeneous. A small percentage of cells was positive for
CCR5 (4.5 ± 1.1 %), CCR6 (4.1 ± 3.8 %), CCR8 (0.9 ±
2.8 %), CXCR1 (3.0 ± 2.4 %), CXCR2 (2.5 ± 3.2 %),
CXCR3 (4.2 ± 3.1 %), CXCR6 (0.3 ± 3.5 %), CXCR7 (2.2
± 1.1 %), and CX3CR1 (2.3 ± 3.1 %). A higher percent-
age of cells was positive for CCR2 (7.8 ± 4.1 %), CCR3
(14.0 ± 4.3 %), CCR4 (6.5 ± 2.1 %), CCR7 (10.9 ± 5.2 %),
CCR9 (8.2 ± 2.9 %), CCR10 (6.1 ± 4.1 %), CXCR4 (7.0 ±
1.7 %), and CXCR5 (8.7 ± 3.5 %) (Fig. 1c). Primary
mADSC culture thus showed a heterogeneous pheno-
type, in which functional chemokine receptors are not
expressed uniformly and only limited yet uncharacter-
ized subsets of ADSC express specific receptors at rela-
tively low levels, suggesting that only a small fraction of
cells is available for effective recruitment of trans-
planted cells into the skin.
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Fig. 1 (See legend on next page.)
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Chemotactic recruitment of mADSC to DEB-affected
blistering and nonblistering skin
Analysis of the blistering and nonblistering skin in 1–2-
day-old Col7a1–/– and wild-type neonatal mice demon-
strated a significant infiltration of the DEB-affected skin
with leukocytes (Fig. 2a). Infiltrates were detected at
both ventral skin and the skin of the extremities, the
most common sites of blister formation in DEB mice.
However, it was particularly noticeable in the blistering
skin where leukocyte infiltrate extended into the blister
cavity (Fig. 2a). Immunophenotyping analysis showed
that about 30 % of CD45+ leukocytes in the wild-type
skin were represented by the CD11b+ cells. The percent-
age of CD11b+ cells in the DEB-affected nonblistering
skin was slightly elevated whereas in blistering skin it
was two times higher (Fig. 2a, b).
Considering elevated levels of CXCR2 ligands, CXCL1,
CXCL2, and CXCL5, in blister fluids, skin-infiltrating
CXCR2+ cells were further quantitated. As expected, in
normal mouse skin about 24 % of CD45+ leukocytes
expressed CXCR2. In DEB-affected nonblistering skin, this
percentage was higher, approaching 45 %. In the blistering
DEB skin, more than 60 % of all leukocytes were CXCR2+.
The prevalence of CD11b+ cells in cutaneous infiltrates and
the high percentage of CXCR2+CD11b+ cells in the blister-
ing skin suggest that higher levels of the CXCR2 ligands,
CXCL1, CXCL2, and CXCL5, in blister fluids may direct in-
tracutaneous migration of the CXCR2+ leukocytes. These
findings also suggest that CXCR2 could mediate homing of
the systemically infused therapeutic type VII collagen-
producing mADSC to the blistering and nonblistering
DEB-affected skin.
Fig. 2 Analysis of wild-type and DEB-affected skin infiltration with leukocytes. a H&E staining and indirect immunofluorescent analysis of skin
infiltration with leukocytes. Detected antigens are shown in respective colors above the panels (CD45, green; CXCR2, green; CD11b, red; colocalization
of CD45 or CXCR2 and CD11b, yellow). Nuclei were counterstained with DAPI (blue). bc blister cavity. Scale bar = 100 μm. b Quantitation of the
skin-infiltrating cells. Data presented as an average number or percentage of cells (as indicated on the Y axis) per microscopic field ± SD. *p <0.05.
**p > 0.05. Data collected from at least 15 independent microscopic fields. CD-positive cell types are shown above the columns. H&E hematoxylin and
eosin, WT wild-type skin, NB nonblistering, DEB dystrophic epidermolysis bullosa, Bl blistering DEB-affected skin
(See figure on previous page.)
Fig. 1 Analysis of chemokines in DEB-associated blister fluids and chemokine receptors on the surface of mADSC. a Chemokine profile in
blister fluids of Col7a1–/– (DEB) and Col7a1f lNeo/f lNeo (Hypo DEB) mice conducted using Proteome Profiler™ Mouse Chemokine Antibody
Array. Blister fluids were collected from blister-affected skin (paw, armpit, neck, and abdomen) of newborn mice. Spot intensities were
normalized based on background levels and positive control signals. Data shown as mean ± SD from three independent arrays (p > 0.05).
b Surface expression of chemokine receptors in primary mADSC on early passage (passages 2–3) detected by flow cytometry. Light gray
curves, control antibody signal; dark shaded curves, specific antibody signal. Histograms are representative examples of chemokine receptor
expression profiles obtained from five independent mADSC preparations. c Quantitation of flow cytometry results for expression of the
chemokine receptors in primary mADSC. Data shown as mean ± SD of cell percentage. DEB dystrophic epidermolysis bullosa
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Cxcr2-mediated homing of the mADSC to the
DEB-affected skin
FASC analysis showed the presence of a small percent-
age of CXCR2-expressing mADSC (2.5 ± 3.2 %) in the
total pool of minimally cultured cells, suggesting that
homing of systemically administered mADSC to the
skin could be enhanced via the use of cells uniformly
expressing CXCR2 receptor. Thus, we generated a
stable cell line of mADSC expressing firefly luciferase
(FLuc+-mADSC) and a derivative line coexpressing
FLuc and mouse Cxcr2 genes (FLuc+CXCR2+-mADSC),
respectively (Fig. 3a). One cohort of wild-type newborn
mice (n = 3 per cohort) and two cohorts of Col7a1–/–
newborn animals (n = 3 per cohort) received an intra-
peritoneal (IP) injection of FLuc+CXCR2+-mADSC and
parental FLuc+-mADSC (5 × 105 cells per injection),
respectively. Twenty-four hours after injection, FLuc
signals were assessed using the AVIS live-imaging sys-
tem. As expected, FLuc activity was found associated with
the intraperitoneal cavity and spleen in all recipient mice
(Fig. 3b). Importantly, FLuc activity signals were readily
detectable in the blister sites located on the paws and the
ventral skin of mice treated with FLuc+CXCR2+-mADSC
but not in animals receiving FLuc+-mADSC transplant.
An additional 24 hours resulted in the accumulation of
the FLuc+CXCR2+-mADSC to the blister sites (Fig. 3b).
H&E staining revealed an increased number of the skin-
infiltrating cells at the blistering skin of mice receiving
FLuc+CXCR2+-mADSC. Infiltrate was mostly noticeable
at both ventral-associated and paw-associated blistering
sites where penetration of infiltrating cells was readily seen
in the blister cavity (Fig. 3c). Indirect immunofluorescent
detection of the FLuc confirmed the presence of the trans-
planted FLuc+CXCR2++-mADSC in the blistering skin,
whereas unselected FLuc+-mADSC were rarely detected
at these sites (Fig. 3d). Double-immunostaining showed
that 40–60 % of CXCR2+ cells express FLuc in ventral and
paw-blistering skin (Fig. 3c, d), suggesting that more than
50 % of skin-recruited cells are represented by the
transplanted FLuc+CXCR2+-mADSC. Further analysis
of FLuc+CXCR2+-mADSC transplant showed the per-
sistent presence of type VII collagen and FLuc double-
positive cells in the upper dermis as well as within the
blister cavity. These double-positive cells represented
about 40–50 % of all transplanted FLuc+ cells (Fig. 3d, e).
Significantly, short stretches of type VII collagen protein
were also detected at the basal layer of the epidermis
(Fig. 3d). Contrary, type VII collagen protein was un-
detectable in the skin of mice receiving unselected FLuc
+-mADSC transplant. Collectively, these studies demon-
strated that transplantation of mADSC uniformly express-
ing CXCR2+ receptor, unlike unselected counterparts,
results in efficient recruitment of stem cells from circula-
tion directly to the blistering skin, where cells exert their
therapeutic function by production of collagen type VII
protein in the proximity of the cutaneous BMZ.
Enrichment of the Cxcr2+-mADSC population for
skin homing
The obtained data demonstrate that genetically engi-
neered CXCR2+-expressing mADSC can be effectively
targeted to the blistering skin due to engagement and
activation of CXCR2 by the DEB skin-producing ligands,
CXCL1, CXCL2, and CXCL5. However, to make this ap-
proach clinically relevant, more generalized stem cell se-
lection strategy to enrich the cells expressing lead
receptors is required. To obtain a CXCR2+-enriched
population, antibody-mediated positive selection of
mADSC on paramagnetic microbeads with consequent
removal of the beads via cleavage of the antibody-bead
linker using CEllection biotin binder kit was tested.
However, this approach did not produce a desirable
number of viable mADSC (data not shown).
Previously, we observed that tissue culture conditions
can significantly affect secretion of chemokines and che-
mokine receptors in bone marrow-derived MSC. In fact,
assessment of chemokine receptors on the surface of
freshly isolated and minimally cultured cells demon-
strated expression of multiple receptors on rather small
populations of the cells. Further analysis of the cell sur-
face expression of CXCR2+ and other potential epithelia-
targeting receptors on mADSC cultured at different
densities and in the presence/absence of selected growth
factors/cytokines was thus tested. FACS-based assess-
ment showed that when cell proliferation was repressed
using a contact inhibition approach by plating high-
density culture exceeding confluency three times and
continued cultured for additional 2 days, a substantial
induction of several chemokine receptors was detected
(Fig. 4a). Exposure of dense cultures to granulocyte
macrophage colony-stimulating factor (GM-CSF; 100 ng/
ml) did not alter expression of chemokine receptors (data
not shown). However, culturing of cells with epidermal
growth factor (EGF; 20 ng/ml) for 48 hours boosted cell
surface expression of CCR4 and CXCR4, whereas treat-
ment with basic fibroblast growth factor (bFGF; 25 ng/
ml) induced CCR3, CCR4, CCR6, and CXCR2 (Fig. 4b).
Interleukin-12 (IL-12; 25 ng/ml) preferentially induced
CCR3, CCR4, CCR9, and CXCR2. Interestingly, trans-
forming growth factor beta (TGF-β; 10 ng/ml) affected
cell surface expression of all examined receptors with
predominant induction of CCR3, CCR6, and CXCR2.
Averagely, exposure of cells to TGF-β led to the en-
richment of the CXCR2+-mADSC population ranging
from 40 to 55 %. Considering the abundance of CXCR2
ligands in blister fluids, expression of CCR3 ligands
(CCL11 and CCL24) in the skin, and expression of CCR4
ligands (CCL17 and CCL22) in dermal microvasculature,
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Fig. 3 Systemic transplantation of genetically engineered CXCR2+-mADSC into DEB-affected newborn mice. a Characterization of CXCR2 expression in
primary mADSC and cells engineered to overexpress FLuc (FLuc+-mADSC) and FLuc and Cxcr2 genes (FLuc+CXCR2+-mADSC), respectively, by FACS and
indirect immunofluorescent detection. Analyses were performed using gene-specific antibodies. (Fluc, red; CXCR2, green; colocalization of FLuc and CXCR2,
yellow; nuclei were counterstained with DAPI). b In-vivo imaging of systemically administered FLuc+CXCR2+-mADSC and native FLuc+-mADSC into new-
born Col7a1–/– and wild-type mice, respectively, 24 and 48 hours after transplantation (as indicated on the left). White and orange arrows point to the blister
location. Type of transplanted cells indicated below the image of a representative mouse. c Representative micrographs of H&E-stained sections of the skin
collected from blistering sites (ventral skin and paws) of FLuc+-mADSC and FLuc+CXCR2+-mADSC transplanted animals, respectively. Black arrowheads point
to infiltrating cells. bc blister cavity. d Indirect immunofluorescent analysis of mADSC recruitment to blistering sites (indicated to the left of the panels). Type
of mADSC used for transplantation indicated above the panels. Detected antigens, FLuc, CXCR2, and Col7, are shown below the panels in corresponding
colors. Scale bar= 100 μm. bc blister cavity, white arrows point to the stretches of the BMZ-associated type VI collagen. e Quantitation of cell recruitment to
blistering sites. Y axis represents the percentage of positive cells per microscopic field. The FLuc+, CXCR2+, and Col7+ cells are shown below the columns.
Data shown as mean ± SD. *p <0.05. **p> 0.05. DEB dystrophic epidermolysis bullosa, mADSC mouse adipose-derived stem cells
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treatment of cells with TGF-β was selected as a stimula-
tory factor for CXCR2+-mADSC enrichment.
Transplantation of the CXCR2-enriched mADSC into
DEB-affected mice
To see whether the selected CXCR2+-mADSC provide
an ADSC population with a functional receptor capable
of directing extravasation at the blistering skin, unse-
lected and CXCR2+-enriched mADSC were delivered via
IP injection (1 × 106 cells/injection/animal) into newborn
1-day-old Col7a1–/– mice (n = 3), respectively. For trans-
plantation of CXCR2+-mADSC, cells on early passage
(passages 2–3) were plated in subconfluent density and
cultured in the presence of TGF-β for 48 hours. To
visualize the recruitment of cells to the blistering skin
along natural CXCL1 + 2 and CXCL5 chemotactic axes,
cells were labeled with Vibrant DiI red fluorescent
tracker. As expected, during the first 24 hours trans-
planted cells were detected mostly at the abdomen, the
site of injection, in both transplanted groups (Fig. 5a).
However, DiI signals were readily detectable at blister-
ing sites on the chest and neck of the mice receiving
CXCR2+-mADSC. Col7a1–/– recipients receiving unse-
lected mADSC transplants demised shortly after trans-
plantation on days 3 and 4. Analysis of the blistering
skin of mice receiving unselected mADSC did not show
any appreciable recruitment of mADSC to the blister-
ing skin. In contrast, all recipients transplanted with
CXCR2+-mADSC survived for at least 1 week without
obvious signs of deterioration, although animals started
to show a runted phenotype. At day 7, migration of
CXCR2+-mADSC from the intraperitoneal cavity to the
Fig. 4 Characterization of cell surface chemokine receptors on mADSC after treatment with selected growth factors and cytokines. a FACS-based
quantitation of the chemokine receptor-positive populations of mADSC under different culture conditions. Selected chemokine receptors
identified on the surface of the cells indicated above the profiles, treatment conditions indicated on the panel: 1× confluent culture, 3×
high-density culture. Treatments that increase populations of chemokine receptor-positive cells are indicated to the right of the profiles.
b Percentage of receptor-positive cells in confluent cultures. Treatment conditions are shown to the right of the graphs. Data shown as
mean ± SD from three independent experiments. *p < 0.05 compared with control (1×) cells
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blistering paws and neck was observed as judged by ac-
cumulation of DiI fluorescent signals. Direct immuno-
fluorescent evaluation of the blistering skin sections
confirmed the presence of DiI+CXCR2+ cells detectable
in the mid and upper dermis and in close proximity to
the blister cavity (Fig. 5b). Indirect immunofluorescent
analysis revealed type VII collagen-positive transplanted
cells just below the epidermis with few cells detectable
at the basal layer. Double-immunostaining with anti-
bodies specific for type IV collagen showed a clear colo-
calization of both proteins at the BMZ (Fig. 5c),
suggesting functionality of the donated protein and par-
tial restoration of the DEJ. Quantitation of the collagen
VII-associated fluorescence by measuring integrated
density at the DEJ showed that transplantation of the
CXCR2+-mADSC led to an increase of the type VII col-
lagen corresponding to 45 % of the wild-type level with
the mean gray value corresponding to 65 % of the wild-
type skin. Collectively, the in-vivo studies demonstrated
that an enriched population of CXCR2+-mADSC can
efficiently migrate toward the blistering skin character-
ized by the elevated levels of CXCR2 ligands and
donate functional therapeutic type protein into the
BMZ of DEB-affected mice.
Discussion
Several clinical studies were conducted to evaluate the
utility of the ASC in alleviating DEB-associated symp-
toms [9, 10, 30, 31]. Although some degree of success
was reported, there is a growing body of evidence that
the observed therapeutic outcome was mainly associated
with the transplanted cell-derived paracrine effects ra-
ther than a direct contribution of the cells to the restor-
ation of the BMZ integrity [10]. One of the potential
pitfalls in achieving desirable therapeutic effects could
be associated with the poor migration and homing of
the systemically transplanted therapeutic cells to the
DEB skin affected with blisters.
Understanding the mechanisms regulating migration
of systemically transplanted ASC is crucial to the success
of any clinical strategy. Here we report a detailed study
to address the chemotactic responsiveness of mADSC to
natural chemotactic gradients in mice affected with se-
vere DEB. To identify key players responsible for
Fig. 5 Transplantation of CXCR2-enriched mADSC into DEB-affected mice. a In-vivo live imaging of neonatal DEB mice and 2 and 7 days after IP
transplantation of the DiI-labeled native and CXCR2+-mADSC (red), respectively. b Direct fluorescent detection of the DiI-mADSC in the blistering
skin of the recipient mice at 7 days after transplantation. Blister cavity (bc) outlined by dotted line. c Indirect immunofluorescent detection of type
VII and type IV collagens in the skin of mADSC-treated and control mice (indicated above the panels). Detected antigens (in corresponding color)
are shown to the left of the panels. Upper row, monochrome images of the sections stained with anti-type VII collagen antibodies. White arrowheads
point to the BMZ. Blue, DAPI nuclear staining. Scale bar = 100 μm. DEB dystrophic epidermolysis bullosa, mADSC mouse adipose-derived stem cells
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disease-targeting of systemically infused cells to the blis-
tering skin, chemotactic signatures of the DEB-
associated blister fluids were investigated by employing
proteome profile screens. The content of chemotactic
molecules in blister fluids showed consistently high
levels of several chemokines, including CCL6, CCL8,
CCL9/10, CCL12, CXCL1, CXCL2, and CXCL5. All
identified molecules are prominent chemotactic factors
that activate and attract various inflammatory cells, in-
cluding lymphocytes, macrophages, neutrophils, and
granulocytes. These data directly suggest that the
presence of elevated levels of identified chemokines
can provide favorable chemotactic axes (CCL8–CCR1,
CCL12–CCR2, CXCL1 + 2–CXCR2, and CXCL5–
CXCR2) for efficient recruitment of the therapeutic
stem cells from the systemic compartment to the
DEB-affected cutaneous tissue. From a clinical per-
spective, the CCL6–CCR1 and CCL9/10–CCR1 axes
can be excluded because the ligands have only been
described in rodents.
Because several of the upregulated chemokines (CXCL1,
CXCL2, and CXCL5) interact with CXCR2 chemokine
receptor, natural recruitment of the CXCR2-positive
leukocytes to the blistering and nonblistering skin of
the DEB-affected mice was further assessed. Analysis
demonstrated that up to 40 % and 70 % of all leuko-
cytes in nonblistering and blistering skin, respectively,
express CXCR2 on the cell surface, suggesting that
CXCR2 ligands play an important role in recruiting
CXCR2+ leukocytes to the blistering sites. Systemic
transplantation of the mADSC engineered to uniformly
express CXCR2 confirmed this notion and demonstrated
preferential recruitment of the CXCR2+-mADSC cells to
blistering skin when compared with a native cell popula-
tion. This observation is in good agreement with prior
studies when chemotactic molecules were used to target
stem cells to specific organs [32, 33]. Recently, we showed
that MSC overexpressing CCR4+ and CCR10+ could be
recruited to epithelial tissue toward an ectopic gradient of
endothelial cell-derived CCL17 and epithelia-derived
CCL27 axes and take part in regeneration/repair of the
skin [7]. Our findings supported the idea that CCR4 en-
gagement is essential for binding to the endothelium
and extravasation, whereas activation of CCR10 is cru-
cial for the directional migration of the cells within the
collagenous matrix. Also, these data suggested distinct
yet synergistic CCR4-dependent and CCR10-dependent
mechanisms of stem cell recruitment to the skin. There
has been much work to investigate the role of the
CXCL12–CXCR4 axis to target MSC to diverse tissues,
including ischemic heart, brain, skeletal muscle, kidney,
liver, and skin [34]. To date, this is the most studied
axis in MSC homing to wounds [24, 35]. Despite this
interest, the majority of these studies investigated cell
homing to sites of burn injury or radiation. In a limited
number of investigations in cutaneous wounds, it was
reported that skin grafts can recruit bone marrow-
derived MSC through stromal derived factor-1α (SDF-
1α, also known as CXCL12)/CXCR4 interaction to
enhance tissue regeneration. Data suggested that dur-
ing a skin graft hypoxic damage to the skin results in
release of a soluble SDF-1α, which in turn recruits
CXCR4+ MSC from circulation to the graft. However,
considering wide expression of CXCL12 in multiple
organs and uninjured tissues, reduced targeting speci-
ficity can significantly dilute the therapeutic effect.
Furthermore, HMGB1 released from the detached or
blistered DEB epithelia was suggested to be a factor in
mobilizing Lin–/PDGFRα+ bone marrow cells into cir-
culation and recruitment of cells to the epidermis and
dermis of grafted Col7-deficient skin on the back of
GFP-BMT mice and acceleration of skin regeneration
[36]. Although an interesting experimental concept,
recruitment of PDGFRα+ cells by HMGB1 does not
provide any homing specificity and strictly depends on
the apoptotic and necrotic status of the tissue. Also,
there are no in-vivo data supporting systemic recruit-
ment of PDGFRα+ cells into the skin of DEB mice.
Based on our comprehensive whole genome oligo
microarray profiles, the primary ADSC naturally ex-
press PDGFRα+ [6]. Moreover, analysis of blister fluids
from patients affected with DEB showed an extremely
low level of PDGFRα+ ligand, PDGF-BB (data not yet
published). However, as shown in this study and our
prior work [7], transplantation of primary heteroge-
neous stem cells failed to provide any appreciable re-
cruitment of cells into the blistering and nonblistering
skin, suggesting that PDGFRα+ alone is not sufficient
to drive effective migration of cells from circulation into
the skin. Taken together, high levels of CXCL1, CXCL2,
and CXCL5 ligands observed in DEB-associated blister
fluids can provide stronger and more specific chemo-
tactic attraction of systemically administered cells ex-
pressing cognate CXCR2 receptor on its surface to the
DEB-affected cutaneous tissue.
Generation of a stable mADSC cell line with engi-
neered CXCR allowed achieving effective homing of
systemically infused cells to blistering skin; however,
genetic manipulation with cells may greatly complicate
clinical application. To develop a strategy aimed at iso-
lation and enrichment of the skin-homing ADSC, two
approaches were considered: antibody-based separation
of CXCR2+ cells on magnetic beads; and alteration of
cell culture protocols. The former approach provided a
good yield of freshly isolated cells after selection on
paramagnetic microbeads but failed to produce sufficient
number of viable cells following enzymatic cleavage of cells
from the beads. The latter strategy, however, demonstrated
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that transient changes in cell culture condition may
substantially enrich a population of cells expressing
desired chemokine receptor. In fact, dense cultures
produced induction of several chemokine receptors,
including CCR3, CCR4, CCR6, CCR9, CXCR2, and
CXCR4. Moreover, exposure of cells to TGF-β signifi-
cantly increased population of cells expressing CXCR2.
TGF-β, alternatively, resulted in induction of other po-
tential skin-homing receptors, including CCR4 and
CCR6, whereas incubation with bFGF altered CCR3
and CXCR2 expression. The presented data thus dem-
onstrate that expression of lead receptors on mADSC
could be altered by temporary changes in tissue cul-
ture conditions and suggest that the stem cells with
disease-organ-specific homing capabilities could be
generated, avoiding time-consuming, labor-retaining,
and expensive selection protocols. At present, very
limited information is available regarding the effect of
various growth factors and cytokines on ADSC-
specific cell surface receptor composition. The major-
ity of studies are focused on optimization of stem cell
proliferation, survival, and differentiation. In fact,
TGF-β, PDGF, and FGF were shown to play an import-
ant role in proliferation of ADSC [37]. Currently, the
focus of stem cell biology is primarily shifted on the
trophic effects elicited by stem cells. Growing data
suggest that therapeutic benefit may not be restricted
to the repair function of cells alone, but also due to
their transient paracrine actions. In fact, current re-
search suggests that stem cells can secrete potent
combinations of trophic factors, such as cytokines,
chemokines, and growth factors, which modulate the
molecular composition of the environment to evoke
responses from resident cells [38]. Although import-
ant, the data presented here also show great promise
and suggest the potential of chemotaxis-driven therapy
to target exogenous cells to distal anatomical sites
such as the skin, emphasizing the need for better cell
selection strategies.
The functionality of the CXCR2+-mADSC population
enriched by exposing cells to TGF-β was further evalu-
ated in a preclinical mouse model of severe DEB. The
cells were systemically transplanted into neonatal mice
via IP injection. Although intravenous (IV) injection
would be more suitable for the systemic transplantation,
an extremely high incidence of pulmonary embolism in
newborn DEB mice did not allow pursuing the IV route.
Nevertheless, IP injection led to a rapid recruitment and
accumulation of the CXCR2+-mADSC in the blistering
skin. Moreover, migrated cells were capable of secreting
type VII collagen, with partial reconstitution of the dam-
aged BMZ. Importantly, an estimate of the fluorescence
intensity indicated that the type VII collagen level corre-
sponded to about 50 % of the wild-type level. Prior
studies demonstrated that 10 % of the BMZ-associated
type VII collagen is enough to stabilize the skin of
Col7a1f lNeo/f lNeo hypomorphic mice [29]. Moreover, in-
jection of 20 × 106 fibroblasts resulted in an increase of
type VII collagen to approximately 30 % of the wild-type
level and provided resistance of the skin against shearing
forces [29]. Our group also demonstrated that intrader-
mal transplantation of only 0.5 × 106 congenic MSC led
to an increase of type VII collagen to about 15 % of the
wild-type level as well as restoration of the damaged DEJ
and protection of the skin from mechanical damage [8].
The data presented here demonstrated that greater de-
position levels of therapeutic protein could be achieved
after systemic transplantation of a rather small number
(0.5 × 106cells/injection) of CXCR2+-enriched mADSC,
emphasizing the great potential of this approach for clin-
ical application. Also, these data are in a good agreement
with recent findings showing that preconditioning of
MSC with TGF-β, TNF-α, and CXCL12 increases secre-
tion of type VII collagen [39], suggesting that pretreat-
ment of cells with a combination of factors stimulating
both the lead receptor and the therapeutic protein may
provide better outcome of transplantation therapy.
Conclusions
In summary, the current study provided experimental
proof that the CXCR2+-mADSC population possesses
blistering skin-homing capabilities allowing targeting of
the therapeutic cells directly to DEB-affected skin along
a natural chemotactic axis and deposition of type VII
collagen into the BMZ with ultimate restoration of the
integrity at the DEJ. Currently ongoing in-vitro and in-
vivo studies will further refine the procedures for the en-
richment of human ADSC with skin-homing capabilities
and the elevated secretion of type VII collagen and other
proteins necessary for proper assembly of the functional
collagen fibers for future allogeneic transplantation to
rescue the DEB phenotype in the patients. Further
mechanistic studies to identify critical factors involved in
chemotactic-based directional migration of the stem
cells will hopefully play an important role in designing
rational approaches toward increasing the efficiency of
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